Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

EUCLIDS: Investigating the immune response to vaccination against Men B in infants

The Oxford Vaccine Group is currently looking to enrol healthy Caucasian children aged 8 to 12 weeks to a study of how children’s immune system responds to the new meningococcal B (MenB) vaccine and to what extent this is affected by different genes. All children enrolled in the study would receive, in addition to their routine immunisations, an immunisation course against meningococcal B, which is not currently available to children in the UK.

We intend to see which genes are important for making a good response to the Men B vaccine by looking at what genes are ‘switched on’ and ‘switched off’ after vaccination. We would also look to see whether the genes that are associated with side effects such as fever are the same ones that are needed for the vaccine to generate a good immune response. This information will help in the design of vaccines that are more effective and have fewer side effects in the future.

The study is open for healthy children aged 8 to 12 weeks, of Caucasian origin, who are yet to receive their vaccinations. The study will consist of 8 to 11 visits over an 11 month period, during which time your child would have 3 doses of the Men B vaccine in addition to their routine vaccines. They would also have 6 blood tests and 2 throat swabs. All study visits would be conducted at your home at a time convenient to you.

For further information on participating in the study, visit the study page.


Similar stories

Why we must expand newborn screening

Early diagnosis is of primary importance both to obtain the best effect of innovative medications and to accelerate their development, writes Professor Laurent Servais.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

Oxford vaccine effective against major B.1.1.7 ‘Kent’ coronavirus strain circulating in the UK

A preprint of ongoing work to assess effectiveness of Oxford’s ChAdOx1 coronavirus vaccine shows that the existing vaccine has similar efficacy against the B.1.1.7 ‘Kent’ coronavirus strain currently circulating in the UK to previously circulating variants.

Children’s pain ‘swept under the carpet for too long’ – Lancet Commission

The launch of Lancet Child and Adolescent Health Commission - the first ever to address paediatric pain - aims to raise the profile of children’s pain from early years to early adulthood.

Oxford COVID-19 vaccine begins human trial stage

University of Oxford researchers have begun testing a COVID-19 vaccine in human volunteers in Oxford today. Around 1,110 people will take part in the trial, half receiving the vaccine and the other half (the control group) receiving a widely available meningitis vaccine.

Funding for new COVID-19 studies awarded to OVG's project on infectious disease immunity in children

Five projects from across Oxford University's Medical Sciences Division, including a project led by Professor Matthew Snape from the Oxford Vaccine Group, are among twenty-one new studies into the novel coronavirus which have been funded by the UK government.